These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32976566)

  • 1. Role and therapeutic potential of liquid-liquid phase separation in amyotrophic lateral sclerosis.
    Pakravan D; Orlando G; Bercier V; Van Den Bosch L
    J Mol Cell Biol; 2021 Apr; 13(1):15-28. PubMed ID: 32976566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Mechanisms of Phase Separation and Amyloidosis of ALS/FTD-linked FUS and TDP-43.
    Song J
    Aging Dis; 2024 Oct; 15(5):2084-2112. PubMed ID: 38029395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAR DNA-binding protein 43 (TDP-43) liquid-liquid phase separation is mediated by just a few aromatic residues.
    Li HR; Chiang WC; Chou PC; Wang WJ; Huang JR
    J Biol Chem; 2018 Apr; 293(16):6090-6098. PubMed ID: 29511089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metals in ALS TDP-43 Pathology.
    Koski L; Ronnevi C; Berntsson E; Wärmländer SKTS; Roos PM
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human TDP-43 and FUS selectively affect motor neuron maturation and survival in a murine cell model of ALS by non-cell-autonomous mechanisms.
    Wächter N; Storch A; Hermann A
    Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(7-8):431-41. PubMed ID: 26174443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "STRESSED OUT": The role of FUS and TDP-43 in amyotrophic lateral sclerosis.
    Aksoy YA; Deng W; Stoddart J; Chung R; Guillemin G; Cole NJ; Neely GG; Hesselson D
    Int J Biochem Cell Biol; 2020 Sep; 126():105821. PubMed ID: 32758633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An aberrant fused in sarcoma liquid droplet of amyotrophic lateral sclerosis pathological variant, R495X, accelerates liquid-solid phase transition.
    Shiramasa Y; Yamamoto R; Kashiwagi N; Sasaki F; Imai S; Ike M; Kitazawa S; Kameda T; Kitahara R
    Sci Rep; 2024 Apr; 14(1):8914. PubMed ID: 38632300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggregation of FET Proteins as a Pathological Change in Amyotrophic Lateral Sclerosis.
    Furukawa Y; Tokuda E
    Adv Exp Med Biol; 2017; 925():1-12. PubMed ID: 27311318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology.
    Ince PG; Highley JR; Kirby J; Wharton SB; Takahashi H; Strong MJ; Shaw PJ
    Acta Neuropathol; 2011 Dec; 122(6):657-71. PubMed ID: 22105541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis.
    Deng HX; Zhai H; Bigio EH; Yan J; Fecto F; Ajroud K; Mishra M; Ajroud-Driss S; Heller S; Sufit R; Siddique N; Mugnaini E; Siddique T
    Ann Neurol; 2010 Jun; 67(6):739-48. PubMed ID: 20517935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals.
    Tamaki Y; Shodai A; Morimura T; Hikiami R; Minamiyama S; Ayaki T; Tooyama I; Furukawa Y; Takahashi R; Urushitani M
    Sci Rep; 2018 Apr; 8(1):6030. PubMed ID: 29662239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis.
    Blair IP; Williams KL; Warraich ST; Durnall JC; Thoeng AD; Manavis J; Blumbergs PC; Vucic S; Kiernan MC; Nicholson GA
    J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):639-45. PubMed ID: 19965854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis.
    Cykowski MD; Powell SZ; Appel JW; Arumanayagam AS; Rivera AL; Appel SH
    Acta Neuropathol Commun; 2018 Apr; 6(1):28. PubMed ID: 29653597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.
    Becker LA; Huang B; Bieri G; Ma R; Knowles DA; Jafar-Nejad P; Messing J; Kim HJ; Soriano A; Auburger G; Pulst SM; Taylor JP; Rigo F; Gitler AD
    Nature; 2017 Apr; 544(7650):367-371. PubMed ID: 28405022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
    Ito D; Suzuki N
    Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cdc48/VCP and Endocytosis Regulate TDP-43 and FUS Toxicity and Turnover.
    Liu G; Byrd A; Warner AN; Pei F; Basha E; Buchanan A; Buchan JR
    Mol Cell Biol; 2020 Jan; 40(4):. PubMed ID: 31767634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations.
    Bäumer D; Hilton D; Paine SM; Turner MR; Lowe J; Talbot K; Ansorge O
    Neurology; 2010 Aug; 75(7):611-8. PubMed ID: 20668261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connecting RNA-Modifying Similarities of TDP-43, FUS, and SOD1 with MicroRNA Dysregulation Amidst A Renewed Network Perspective of Amyotrophic Lateral Sclerosis Proteinopathy.
    Pham J; Keon M; Brennan S; Saksena N
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggresome formation and liquid-liquid phase separation independently induce cytoplasmic aggregation of TAR DNA-binding protein 43.
    Watanabe S; Inami H; Oiwa K; Murata Y; Sakai S; Komine O; Sobue A; Iguchi Y; Katsuno M; Yamanaka K
    Cell Death Dis; 2020 Oct; 11(10):909. PubMed ID: 33097688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular mechanism of amyotrophic lateral sclerosis (ALS) from the viewpoint of the formation and degeneration of transactive response DNA-binding protein 43 kDa (TDP-43) inclusions].
    Kasahara S; Ishihara T; Koike Y; Sugai A; Onodera O
    Rinsho Shinkeigaku; 2020 Feb; 60(2):109-116. PubMed ID: 31956195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.